Clinical Trial

Evaluation of TL-925 for the Treatment of Seasonal Allergic Conjunctivitis

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated November 25, 2025 (before its estimated February 2026 completion). Its status may not reflect the trial's current state.
Summary
In this prospective, Phase 2, randomized, double-masked, vehicle controlled study, approximately 60 eligible subjects will be randomized 1:1 to receive either TL-925 or placebo as topical ophthalmic eye drops administered bilaterally. The study comprises of a screening and treatment period using the conjunctival allergen challenge model to evaluate TL-925 for the treatment of allergic conjunctivitis.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-10-21.
Status change: Not Yet Recruiting → Recruiting 2025-11-22
Trial Details
NCT Number NCT07220408
Lead Sponsor Telios Pharma, Inc.
Conditions Allergic Conjunctivitis
Enrollment 60 participants
Start Date 2025-10-23
Primary Completion 2026-02 (estimated)
Study Completion 2026-02 (estimated)
Updated on ClinicalTrials.gov 2025-11-25